Opportunistic pathogen

机会性病原体
  • 文章类型: Journal Article
    柠檬酸杆菌koseri(C.koseri)是革兰氏阴性的,能动,属于肠杆菌科的非孢子形成兼性厌氧杆菌。C.koseri通常利用柠檬酸盐作为唯一的碳源并且构成人和动物的正常胃肠菌群的一部分。作为一种机会性病原体,C.koseri感染主要在新生儿中观察到,老年人,和免疫受损的宿主。C.koseri已成为新生儿脑膜炎和脑脓肿的主要病因之一。近年来,据报道,由C.koseri引起的严重感染的成人病例越来越多。这里,我们首次报道一例重症哮喘患者并发C.koseri腹腔感染的临床病例,并对相关文献进行简要回顾.有了这份报告,我们希望提高临床医生对需要长期口服糖皮质激素的哮喘患者并发肠道共生菌感染可能性的认识和警觉性.
    Citrobacter koseri (C. koseri) is a Gram-negative, motile, non-spore-forming facultative anaerobic bacillus belonging to the Enterobacteriaceae family. C. koseri typically utilizes citrate as the sole carbon source and constitutes part of the normal gastrointestinal flora in humans and animals. As an opportunistic pathogen, C. koseri infections are mainly observed in neonates, elderly individuals, and immunocompromised hosts. C. koseri has been one of the main etiological agents of neonatal meningitis and cerebral abscess. In recent years, an increasing number of cases have been reported in adults with severe infections caused by C. koseri. Here, we report for the first time a clinical case of concurrent C. koseri intra-abdominal infection in a patient with severe asthma and provide a brief review of the relevant literature. With this report, we hope to increase awareness and alertness among clinicians to the possibility of concurrent infection of gut commensal bacteria in asthmatic patients requiring long-term oral corticosteroid administration.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    耐碳青霉烯类鲍曼不动杆菌(CRAB)已被世界卫生组织列为需要紧急新抗生素治疗选择的关键病原体类别。头孢地洛,第一个批准的铁载体头孢菌素,被设计用于治疗CR革兰氏阴性病原体,特别是非发酵物种鲍曼不动杆菌和铜绿假单胞菌。头孢地洛对丝氨酸和金属β-内酰胺酶的水解大多稳定,这是导致碳青霉烯耐药的主要原因。这篇综述整理了关于体外活性的现有证据,药代动力学/药效学,头孢地洛的疗效和安全性,并概述了其目前在CRAB感染管理中的作用。体外监测数据显示头孢地洛对CRAB分离株的敏感性>90%,以及与指南中推荐的多种抗生素的体外协同作用。头孢地洛单药治疗CRAB感染的临床疗效已在描述性,开放标签可信CR和非劣效性,双盲APEKS-NP随机临床试验和有潜在健康问题患者的实际病例。迄今为止,鲍曼不动杆菌对头孢地洛的耐药性在治疗中发展的频率似乎很低,但强烈建议进行监测。在目前的中重度CRAB感染治疗指南中,推荐头孢地洛用于其他抗生素失败的感染,并与其他活性抗生素联合使用。体内临床前数据支持舒巴坦或阿维巴坦与头孢地洛的组合可增强功效并抑制对头孢地洛的耐药性的出现。联合治疗在临床环境中的益处尚未在前瞻性研究中确定。
    Carbapenem-resistant Acinetobacter baumannii (CRAB) has been classified by the World Health Organization as being in the critical category of pathogens requiring urgent new antibiotic treatment options. Cefiderocol, the first approved siderophore cephalosporin, was designed for the treatment of carbapenem-resistant Gram-negative pathogens, particularly the non-fermenting species A. baumannii and Pseudomonas aeruginosa. Cefiderocol is mostly stable against hydrolysis by serine β-lactamases and metallo-β-lactamases, which are leading causes of carbapenem resistance. This review collates the available evidence on the in vitro activity, pharmacokinetics/pharmacodynamics, and efficacy and safety of cefiderocol, and outlines its current role in the management of CRAB infections. In vitro surveillance data show susceptibility rates of >90% for cefiderocol against CRAB isolates as well as in vitro synergism with a variety of antibiotics recommended in guidelines. Clinical efficacy of cefiderocol monotherapy against CRAB infections has been demonstrated in the descriptive, open-label CREDIBLE-CR and the non-inferiority, double-blind APEKS-NP randomised clinical trials as well as in real-world cases in patients with underlying health problems. To date, the frequency of on-therapy development of cefiderocol resistance in A. baumannii appears to be low, but monitoring is highly recommended. Within current treatment guidelines for moderate-to-severe CRAB infections, cefiderocol is recommended for infections in which other antibiotics failed and in combination with other active antibiotics. In vivo pre-clinical data support the combination of sulbactam or avibactam with cefiderocol to enhance efficacy and to suppress the emergence of cefiderocol resistance. The benefit of combination therapy in the clinical setting is yet to be determined in prospective studies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Review
    粘质沙雷氏菌是肠杆菌中普遍存在的细菌,表现出高度的遗传可塑性,使其能够适应并持续存在于包括土壤在内的多个生态位,水,植物,和医院环境。最近,S.marcescens作为一种新兴的病原体在全球范围内受到关注,在衰弱的个体中引发感染和爆发,特别是新生儿和重症监护病房的病人。从临床环境中回收的粘质链球菌分离株通常被描述为多药耐药。在沙雷氏菌物种中高水平的抗生素抗性是内在,收购,和自适应电阻元件。在这次审查中,我们将讨论在这种机会性病原体中指导抗性的机制的理解的最新进展。
    Serratia marcescens is a ubiquitous bacterium from order Enterobacterales displaying a high genetic plasticity that allows it to adapt and persist in multiple niches including soil, water, plants, and nosocomial environments. Recently, S. marcescens has gained attention as an emerging pathogen worldwide, provoking infections and outbreaks in debilitated individuals, particularly newborns and patients in intensive care units. S. marcescens isolates recovered from clinical settings are frequently described as multidrug resistant. High levels of antibiotic resistance across Serratia species are a consequence of the combined activity of intrinsic, acquired, and adaptive resistance elements. In this review, we will discuss recent advances in the understanding of mechanisms guiding resistance in this opportunistic pathogen.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    As a genus that has evolved for resistance against adverse environmental factors and that readily exchanges genetic elements, enterococci are well adapted to the cheese environment and may reach high numbers in artisanal cheeses. Their metabolites impact cheese flavor, texture, and rheological properties, thus contributing to the development of its typical sensorial properties. Due to their antimicrobial activity, enterococci modulate the cheese microbiota, stimulate autolysis of other lactic acid bacteria (LAB), control pathogens and deterioration microorganisms, and may offer beneficial effects to the health of their hosts. They could in principle be employed as adjunct/protective/probiotic cultures; however, due to their propensity to acquire genetic determinants of virulence and antibiotic resistance, together with the opportunistic character of some of its members, this genus does not possess Qualified Presumption of Safety (QPS) status. It is, however, noteworthy that some putative virulence factors described in foodborne enterococci may simply reflect adaptation to the food environment and to the human host as commensal. Further research is needed to help distinguish friend from foe among enterococci, eventually enabling exploitation of the beneficial aspects of specific cheese-associated strains. This review aims at discussing both beneficial and deleterious roles played by enterococci in artisanal cheeses, while highlighting the need for further research on such a remarkably hardy genus.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    BACKGROUND: Serratia spp. is a common enteric bacterium generally thought not to be pathogenic in the gastrointestinal tract. Serratia marcescens is a member of the genus Serratia, which is a part of the family Enterobacteriales..Of all Serratia species, S. marcescens is the most common clinical isolate and the most important human pathogen.
    OBJECTIVE: We are discussing here four cases of Serratia marcescens which we reported in our laboratory in the Department of Microbiology Government Medical College and Hospital Chandigarh during six months of duration.
    METHODS: All the samples were processed and identified as per standard microbiological techniques.The isolates of Serratia marcescens were identified, depending upon their biochemical and morphological characters and further confirmed by MALDI-TOF-MS ,PGIMER Chandigarh.
    RESULTS: In one of the four cases there was polymicrobial infection and one patient was diabetic and rest three patients were immunocompetent. The importance of detection and reporting of Serratia marcescens is related to the concern regarding its increase spread in hospital settings as nosocomial infection .
    CONCLUSIONS: We need to identify and isolate this pathogen ,not thinking of only contaminant and opportunistic pathogen but as a pathogen which can lead to serious infections in hospital settings .
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    BACKGROUND: Madelung\'s disease (MD) is a rare disorder of fat metabolism, which is usually associated with diabetes, hyperuricemia, liver disease, nevertheless there is no report of a patient with MD and pulmonary aspergillosis (PA). This article aimed to enhance the awareness of this two diseases and discuss the possible mechanism of the combination of them preliminarily.
    METHODS: In this case, we described a 56-year-old male patient with cough, expectoration and dyspnea. His neck has a very peculiar appearance. Chest enhanced CT scan showed there were multiple nodules in both lungs, some of which had cavities and the mediastinal lymph nodes were swollen. Ultrasound scan of the neck showed diffuse hyperplasia of subcutaneous fat in neck and bilateral supraclavicular fossa. Fortunately, after performing pulmonary wedge resection aimed at pathological examination and giving relevant treatments, this patient was finally diagnosed as MD with PA, and his symptoms were significantly relieved.
    CONCLUSIONS: MD is rare, the phenomenon that MD combined with PA is rarer. Immune disorder may be the possible mechanism.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号